Table II.
Seated Clinic Trough Blood Pressures (BPs) and Changes From Baseline by Treatment Group
| BP Measurements, mm Hg | Telmisartan‐HCTZ 80/25 mg (n=467) | Valsartan‐HCTZ 160/25 mg (n=479) | Placebo (n=120) |
|---|---|---|---|
| Systolic | |||
| Observed, mean (SD) | |||
| Baseline | 154.6 (11.5) | 154.3 (11.9) | 154.6 (13.1) |
| Final | 130.5 (16.0) | 133.2 (15.6) | 150.1 (16.0) |
| Change from baseline | −24.0 (14.7) | −21.2 (15.4) | −4.4 (13.8) |
| Adjusted* change from baseline, mean (SE) | −23.6 (0.70) | −20.9 (0.70) | −3.9 (1.3) |
| Comparison to telmisartan‐HCTZ, difference (95% CI) | −2.8 (−4.6 to −1.0)† | −19.6 (−22.4 to −16.8)‡ | |
| Diastolic | |||
| Observed, mean (SD) | |||
| Baseline | 101.8 (4.0) | 101.9 (4.3) | 101.9 (3.9) |
| Final | 84.2 (9.7) | 85.8 (9.6) | 95.1 (10.2) |
| Change from baseline | −17.6 (8.9) | −16.1 (9.0) | −6.8 (9.3) |
| Adjusted* change from baseline, mean (SE) | −17.5 (0.4) | −16.1 (0.4) | −6.7 (0.8) |
| Comparison to telmisartan‐HCTZ, difference (95% CI) | −1.8(−3.0 to −0.6)§ | −10.8 (−12.5 to −9.0)† | |
| HCTZ indicates hydrochlorothiazide; SE, standard error; and CI, confidence interval. *Adjusted for gender and race with both baseline response and age as covariates. †P=.0039; ‡P<.0001; §P=.0190. | |||